Expanding treatment options for rosacea

Hampton, Philip

doi:10.1111/bjd.18985

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review, including GRADE assessments on interventions for rosacea, has been especially helpful for clinical decision-making [19,20]. However, treatment options for rosacea should also be expanded because managing rosacea remains a challenge [21]. The focus of this review is the expansion of treatment options rather than the level of evidence and the degree of recommendations, with the aim to summarize and update treatment options for rosacea and to supplement recent guidelines and expert consensuses.…”

Section: Introductionmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Rosacea is a chronic and inflammatory skin disease characterized by flushing, nontransient erythema, papules/pustules, telangiectasia, and phymatous changes. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea. In 2017, a phenotype-based approach for diagnosis and classification was recommended. With the update of the diagnosis and classification of rosacea, treatment options for patients with rosacea have attracted the attention of dermatologists. Here, we summarize the latest advances in rosacea treatment, including skin care and cosmetic treatments, topical therapies, oral therapies, laser- and light-based therapies, injection therapies, treatments for specific types of rosacea, treatments for systemic comorbidities, and combination therapies. The impact of the phenotype-based approach on rosacea treatment and future directions are also discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Although its prevalence varies among countries, it ranges between 1% and 20%, is more common in women between the ages of 30-50 and in people who have skin phenotype as 1-3. It can be seen in the central region of the face, which is always visible, in various clinical forms with erythema, telangiectasia, rhinophyma, papules, and pustules (1,2). There are 4 subtypes of Rosacea identified as Erythematotelengiectatic, Papulopustular, Phymatous, and Ocular (3).…”

Section: Introductionmentioning

confidence: 99%

Rosacea-Specific Quality of Life Scale (RosaQoL): The Study of Adaptation and Validation for Turkish Rosacea Patients

Tosun

Karagöz

2022

Clinical and Experimental Health Sciences

View full text Add to dashboard Cite

Objective: Rosacea-Specific Quality of Life Scale (RosaQoL) developed specifically for rosacea. The aim of the study was to adapt the RosaQoL Scale that is specific to Rosacea used in evaluating the quality of life of patients with Rosacea into Turkish, and evaluate its validity and reliability. Methods: The RosaQoL Scale is a 21-item index that is specific to Rosacea, and was developed originally in English. The Turkish Scale, which was created after the clinical examinations of the patients, was applied to the patients. A total of 285 people, 240 females (84.2%) and 45 males (15.8%), who were diagnosed with Rosacea, admitting to the dermatology clinic between May 2019 and August 2019 were included in the study. Results: The mean age of the patients was found to be 44.8 ± 12.5 years in the study. The internal consistency of the scale (Cronbach’s Alpha Coefficient) was found to be 0.952. The correlation coefficient was calculated as r=0.988 in the test-retest reliability. The total RosaQoL score was 62.4 ± 11.5 (Mean ± SD), and the total DLQI score was 7.85 ± 5.04 (Mean ± SD). For validity analysis, the correlation coefficient between RosaQoL and DLQI was calculated as r=0.411 (p

show abstract